Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | FUCA1 | P04066 | 5/20 | 0.44 |
| ▸ | ARG1 | P05089 | 1/20 | 0.44 |
| ▸ | FUCA2 | Q9BTY2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.41 |
| ▸ | MAN2B2 | Q9Y2E5 | 1/20 | 0.41 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12909445 | 1.00 | PKM (0.45) | PKMFUCA1ARG1FUCA2ALDH1A1 | |
| SCHEMBL944158 | 1.00 | PKM (0.45) | PKMFUCA1ARG1FUCA2ALDH1A1 | |
| SCHEMBL942167 | 1.00 | PKM (0.45) | PKMFUCA1ARG1FUCA2ALDH1A1 | |
| SCHEMBL941276 | 1.00 | PKM (0.45) | PKMFUCA1ARG1FUCA2ALDH1A1 | |
| SCHEMBL15599050 | 1.00 | PKM (0.45) | PKMFUCA1ARG1FUCA2ALDH1A1 | |
| SCHEMBL24518229 | 1.00 | PKM (0.45) | PKMFUCA1ARG1FUCA2ALDH1A1 | |
| SCHEMBL17795749 | 1.00 | PKM (0.45) | PKMFUCA1ARG1FUCA2ALDH1A1 | |
| SCHEMBL6284997 | 1.00 | PKM (0.45) | PKMFUCA1ARG1FUCA2ALDH1A1 | |
| SCHEMBL12325135 | 1.00 | PKM (0.45) | PKMFUCA1ARG1FUCA2ALDH1A1 | |
| Water SCHEMBL17784184 | 0.98 | PKM (0.43) | PKMFUCA1ARG1FUCA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2957295-B1 | METHOD FOR TREATING ALZHEIMER'S DISEASE USING PHARMACOLOGICAL CHAPERONES TO INCREASE THE ACTIVITY OF GANGLIOSIDASES | AMICUS THERAPEUTICS INC (US) | 2017-08-02 | — | — | EP | claimed |
| EP-2490712-B1 | METHOD FOR TREATING ALZHEIMER'S DISEASE USING PHARMACOLOGICAL CHAPERONES TO INCREASE THE ACTIVITY OF GANGLIOSIDASES | AMICUS THERAPEUTICS INC (US) | 2015-07-08 | — | — | EP | claimed |
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | MODERNATX, INC. | 2022-06-16 | — | — | US | disclosed |
| EP-4003520-A1 | BIOACTIVE PHYTOCHEMICALS | Phytoquest Limited (GB) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021019194-A1 | BIOACTIVE PHYTOCHEMICALS | PHYTOQUEST LIMITED (GB) | 2021-02-04 | — | — | WO | disclosed |
| US-10842784-B2 | Treatment of energy utilization disease | VIDA PHARMA LIMITED (GB) | 2020-11-24 | — | — | US | disclosed |
| US-10842784-B2 | Treatment of energy utilization disease | VIDA PHARMA LIMITED (GB) | 2020-11-24 | — | — | US | disclosed |
| WO-2020023390-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | MODERNATX, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| US-9931353-B2 | Method for treating cerebral amyloid angiopathy using pharmacological chaperones to increase the activity of gangliosidases | AMICUS THERAPEUTICS, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20180002275-A1 | HYPDH INHIBITORS AND METHODS OF USE FOR THE TREATMENT OF KIDNEY STONES | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2018-01-04 | — | — | US | disclosed |
| EP-2957295-B1 | METHOD FOR TREATING ALZHEIMER'S DISEASE USING PHARMACOLOGICAL CHAPERONES TO INCREASE THE ACTIVITY OF GANGLIOSIDASES | AMICUS THERAPEUTICS INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-6599919-B2 | Administering reversible competitive inhibitor of enzyme in an amount effective to enhance activity of enzyme in cell | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY | 2003-07-29 | — | — | US | disclosed |
| US-6589964-B2 | Administering a competitive inhibitor of the enzyme in an amount effective to enhance enzyme activtiy, selected from 2,5-dideoxy- 2,5-imino-D-mannitol, 3,4-diepi- alpha -homonojirimycin, 5-O- deoxyglactonojirimycin, calystegines | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY | 2003-07-08 | — | — | US | disclosed |
| US-6583158-B1 | Competitive inhibitors of the enzymes, in particular imino sugars and related compounds | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY | 2003-06-24 | — | — | US | disclosed |
| EP-0433978-B1 | New process for the preparation of nojirimycin and related compounds | MERRELL PHARMA INC (US) | 1996-05-08 | — | — | EP | disclosed |
| EP-0359263-B1 | Synthesis of intermediate useful in the preparation of nojirimycin and related compounds | MERRELL DOW PHARMA (US) | 1995-06-28 | — | — | EP | disclosed |
| US-5227479-A | PROCESS FOR THE PREPARATION OF NOJIRIMYCIN AND RELATED COMPOUNDS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-07-13 | — | — | US | disclosed |
| EP-0433978-A2 | New process for the preparation of nojirimycin and related compounds | MERRELL PHARMACEUTICALS INC. (US) | 1991-06-26 | — | — | EP | disclosed |
| EP-0359263-A2 | Synthesis of intermediate useful in the preparation of nojirimycin and related compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-21 | — | — | EP | disclosed |
| US-4908439-A | Synthesis of intermediate useful in the preparation of nojirimycin and related compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10842784-B2 | Treatment of energy utilization disease | IRS1, SLC2A1, INSR | PKM 456/4885FUCA1 1506/4885ARG1 610/4885 |
| US-20180002275-A1 | HYPDH INHIBITORS AND METHODS OF USE FOR THE TREATMENT OF KIDNEY STONES | XDH, GLS, GRHPR | PKM 1364/4885FUCA1 625/4885ARG1 312/4885 |
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | GAA, GBA1, GBA2 | PKM 1841/4885FUCA1 15/4885ARG1 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.